New drugs for asthma

被引:162
作者
Barnes, PJ [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, London SW3 6LY, England
关键词
D O I
10.1038/nrd1524
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Asthma is a major and increasing global health problem and, despite major advances in therapy, many patients' symptoms are not adequately controlled. Treatment with combination inhalers, which contain a corticosteroid and long-acting beta(2) adrenoceptor agonist, is the most effective current therapy. There is therefore a search for new therapies, particularly safe and effective oral treatments and those that are more efficacious in severe asthma. New therapies in development include mediator antagonists and inhibitors of cytokines, although these therapies might be too specific to be very effective. New anti-inflammatory therapies include corticosteroids and inhibitors of phosphodiesterase-4, p38 mitogen-activated protein kinase and nuclear factor-kappaB. The prospects for a curative treatment are on the horizon.
引用
收藏
页码:831 / 844
页数:14
相关论文
共 170 条
[1]   Selectin blockade prevents antigen-induced late bronchial responses and airway hyperresponsiveness in allergic sheep [J].
Abraham, WM ;
Ahmed, A ;
Sabater, JR ;
Lauredo, IT ;
Botvinnikova, Y ;
Bjercke, RJ ;
Hu, X ;
Revelle, BM ;
Kogan, TP ;
Scott, IL ;
Dixon, RAF ;
Yeh, ETH ;
Beck, PJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (04) :1205-1214
[2]  
Adachi T, 1999, J IMMUNOL, V163, P939
[3]   Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation:: preferential targetting of NF-κB and lack of I-κB involvement [J].
Adcock, IM ;
Nasuhara, Y ;
Stevens, DA ;
Barnes, PJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 127 (04) :1003-1011
[4]   Medicinal chemistry and therapeutic potential of CpG DNA [J].
Agrawal, S ;
Kandimalla, ER .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (03) :114-121
[5]   Src family-selective tyrosine kinase inhibitor, PP1, inhibits both Fc epsilon RI- and Thy-1-mediated activation of rat basophilic leukemia cells [J].
Amoui, M ;
Draber, P ;
Draberova, L .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (08) :1881-1886
[6]   EFFECT OF INHALED ATRIAL-NATRIURETIC-PEPTIDE AND A NEUTRAL ENDOPEPTIDASE INHIBITOR ON HISTAMINE-INDUCED BRONCHOCONSTRICTION [J].
ANGUS, RM ;
MILLAR, EA ;
CHALMERS, GW ;
THOMSON, NC .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 151 (06) :2003-2005
[7]   Interleukin-1 receptor antagonist: Role in biology [J].
Arend, WP ;
Malyak, M ;
Guthridge, CJ ;
Gabay, C .
ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :27-55
[8]   Functional characteristics of cysteinyl-leukotriene receptor subtypes [J].
Bäck, M .
LIFE SCIENCES, 2002, 71 (06) :611-622
[9]   Anti-leukotrienes: here to stay? [J].
Barnes, PJ .
CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (03) :257-263
[10]  
BARNES PJ, 1984, AM REV RESPIR DIS, V130, P162